Antisense Oligonucleotides
On this page
Direct answer
An antisense oligonucleotide is a short synthetic strand — typically 18 to 25 bases — engineered to base-pair with one specific RNA and change its fate, and everything depends on two design choices. Gapmers carry an unmodified DNA core flanked by modified RNA wings: RNase H1 recognises the RNA-DNA duplex and cuts the RNA, silencing the gene. Fully modified splice-switching oligomers do not cut anything; they physically block splice sites or silencer motifs — the mechanism of nusinersen, which binds the ISS-N1 site in SMN2 pre-mRNA so that exon 7 is retained and functional SMN protein is produced in spinal muscular atrophy. Naked DNA would last minutes; phosphorothioate backbones, 2'-O-methyl and morpholino chemologies make the drugs survive.
What you must remember
- Two mechanisms, cleanly separated: RNase H1-mediated cleavage (gapmers — mipomersen against apoB for homozygous familial hypercholesterolaemia; inotersen against transthyretin in hereditary amyloidosis) versus steric-block splice modulation (nusinersen, eteplirsen).
- Nusinersen specifics: 2'-O-methoxyethyl phosphorothioate chemistry, intrathecal administration, four loading doses then maintenance roughly every four months; transforms the natural history of infantile-onset SMA when started early.
- Eteplirsen: a phosphorodiamidate morpholino (PMO) restoring the reading frame of Duchenne dystrophin by exon-51 skipping.
- Why chemistry is everything: phosphodiester DNA is shredded by nucleases and triggers innate immunity; phosphorothioate substitution resists nucleases and binds plasma proteins, extending half-life.
- First in class: fomivirsen, 1998, against CMV retinitis — the first approved antisense drug, later withdrawn as its indication faded; it remains the historical one-liner.
- ASO versus siRNA: antisense works through RNase H or steric blocking with a single strand; siRNA (patisiran for ATTR) loads Argonaute in RISC to slice the target — a mechanism pair examiners explicitly contrast.
- Delivery logic: intrathecal for spinal cord targets, GalNAc conjugation for hepatocyte uptake — the liver is the easy organ, the brain the hard one.
- Safety flags: thrombocytopenia and renal monitoring with inotersen; injection-site reactions with subcutaneous gapmers.
Nusinersen, from genotype to injection
Spinal muscular atrophy deletes or disables SMN1, yet every patient carries SMN2, a near-copy that differs by a C-to-T transition causing exon 7 to be skipped in most transcripts — a truncated, rapidly degraded protein. Nusinersen binds the ISS-N1 intronic silencer just upstream of exon 7, physically preventing repressor splicing factors from sitting there, so the spliceosome includes exon 7 and full-length SMN is produced from the backup gene. SMN2 copy number explains disease severity (infants with two copies are worst affected) and predicts response — a genotype-therapy correlation students can recite end to end. Because the oligomer does not cross the blood-brain barrier, it is given by lumbar puncture into the CSF, reaching motor neurons directly. Distinguish it from onasemnogene abeparvovec, which delivers a functional SMN1 by viral vector — the ASO is RNA therapy, not gene therapy, and saying so cleanly is the mark of a prepared candidate. Access in India remains limited by cost, a real-world caveat worth one measured sentence.
Where students slip
The first slip is mechanical: "antisense always degrades RNA" — splice-switching oligomers never touch RNase H; nusinersen blocks, it does not cut, and this is precisely why it needs full modification rather than a DNA gap. The second is lumping nusinersen with gene therapy, corrected above. The third is forgetting why modifications exist at all — a question that invites the nuclease-and-immunity answer, not just a list of chemical names. Fourth, ASO versus siRNA: single-stranded RNase-H/steric-block acting alone versus double-stranded RISC-dependent slicer — if an examiner supplies patisiran, name the siRNA mechanism unprompted. The intrathecal route is not a detail; it is the answer to "why not oral", and connecting BBB impermeability to route of administration shows clinical reasoning, not recall.
Frequently asked questions
What are the two mechanisms of antisense oligonucleotide action?
RNase H1 cleavage of the RNA-DNA duplex in gapmers, and steric blockade — masking splice sites or translation starts — by fully modified oligomers without any cleavage.
Why must antisense oligonucleotides be chemically modified?
Unmodified DNA is rapidly degraded by nucleases and can activate innate immune sensors; phosphorothioate, 2'-O modifications and morpholinos confer stability and tune pharmacokinetics.
What does nusinersen target, and how is it given?
It binds the ISS-N1 site of SMN2 pre-mRNA to promote exon 7 inclusion, and it is given by intrathecal injection because it cannot cross the blood-brain barrier.
How does an siRNA drug differ from an antisense oligonucleotide?
siRNA is double-stranded and works through the RISC-Argonaute slicer complex, while ASOs are single strands acting via RNase H or steric blockade.
Which was the first approved antisense drug?
Fomivirsen, licensed in 1998 for cytomegalovirus retinitis in AIDS patients and later withdrawn from the market as its indication disappeared.